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ABSTRACT
The muscular dystrophy X-linked (mdx) mouse is commonly used as
a mouse model of Duchenne muscular dystrophy (DMD). Its
phenotype is, however, mild, and other mouse models have been
explored. The mdx:Cmah−/− mouse carries a human-like mutation in
the Cmah gene and has a severe muscle phenotype, but its growth
and bone development are unknown. In this study, we compared
malemdx,mdx:Utrn+/−,mdx:Cmah−/− andwild-type (WT)mice at 3, 5
and 7 weeks of age to determine the suitability of the mdx:Cmah−/−
mouse as a model for assessing growth and skeletal development in
DMD. Themdx:Cmah−/−mice were lighter than WT mice at 3 weeks,
but heavier at 7 weeks, and showed an increased growth rate at
5 weeks. Cortical bone fraction as assessed by micro-computed
tomography was greater in both mdx and mdx:Cmah−/− mice versus
WT mice at 7 weeks. Tissue mineral density was also higher in mdx:
Cmah−/−mice at 3 and 7 weeks. Gene profiling ofmdx:Cmah−/− bone
identified increased expression of Igf1, Igf1r and Vegfa. Both themdx
andmdx:Cmah−/−mice showed an increased proportion of regulated
bone marrow adipose tissue (BMAT) but a reduction in constitutive
BMAT. The mdx:Cmah−/− mice show evidence of catch-up growth
and more rapid bone development. This pattern does not mimic the
typical DMD growth trajectory and therefore the utility of the mdx:
Cmah−/− mouse for studying growth and skeletal development in
DMD is limited. Further studies of this model may, however, shed light
on the phenomenon of catch-up growth.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) affects 1 in 4000 live male
births and is a severe and ultimately fatal X-linked recessive disease
(Emery, 1991). Although progression of DMD can be slowed with
the administration of glucocorticoids (GCs), therapy is often
associated with growth retardation and skeletal fragility (Biggar
et al., 2006; Joseph et al., 2019). However, it is clear that growth
impairment and fractures are also prevalent in steroid-naïve boys
with DMD (Rapaport et al., 1991; Larson and Henderson, 2000;
Matsumoto et al., 2017), suggesting that there may be an intrinsic
abnormality of growth and skeletal development in DMD (Eiholzer
et al., 1988). Specifically, an older retrospective study that was
carried out before GC therapy became standard of care found that
44% of steroid-naïve DMD boys had sustained a fracture (Larson
and Henderson, 2000). A more recent in vivo and clinical study has
also suggested that an abnormality of osteoblast function may exist
in bones of DMD patients (Rufo et al., 2011). To improve our
understanding of the underlying defect in growth and skeletal
development in DMD, there is a critical need to identify an animal
model that closely mimics these clinical features of DMD.
The muscular dystrophy X-linked (mdx) mouse is the most
commonly used and best-characterised animal model of DMD, but
it has limited applicability in humans as the muscle phenotype is
much less severe (Bulfield et al., 1984; Muntoni et al., 1993). Acute
muscle necrosis by 3 weeks of age is followed by subsequent
muscle regeneration and the overall lifespan of the mdx mouse is
nearly normal (Chamberlain et al., 2007). In contrast to the
relentless decline in muscle function in humans, the muscle force of
mdx limb muscles is near normal until the mice become aged
(Lynch et al., 2001; Muller et al., 2001). The utrophin heterozygous
mdx mouse (mdx:Utrn+/−) may represent an intermediate model
between the extreme mdx:Utrn double-knockout mouse (mdx:
Utrn−/−), which rarely survives beyond 20 weeks of age (Gao et al.,
2019), and the more mildly affected mdx mouse. Utrophin is an
autosomal homologue of dystrophin and its upregulation in the mdx
mouse may compensate for the lack of dystrophin, thereby
accounting for the less-severe phenotype compared to DMD in
humans (Grady et al., 1997). However, the growth and skeletal
development of the mdx:Utrn+/− mouse has not previously been
studied in detail.
An alternative murine model of DMD is themdx:Cmah−/−mouse.
This carries a human-like mutation in the cytidine monophospho-
N-acetylneuraminic acid hydroxylase (Cmah) gene that prevents
synthesis of the sialic acid, N-glycolylneuraminic acid (Chou et al.,
1998; Chandrasekharan et al., 2010). The mdx:Cmah−/− mouse has
been reported to have phenotypic and molecular similarities to
human DMD, and also displays increased disease severity and
reduced lifespan compared to the mdx mouse (ChandrasekharanReceived 26 May 2019; Accepted 12 November 2020
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et al., 2010). The mdx:Cmah−/− mouse may therefore be a more
appropriate murine model for DMD, but its growth and skeletal
phenotypes have not yet been characterised.
Bone marrow adipose tissue (BMAT) has attracted recent interest
as a further biomarker of bone integrity and fracture risk, with
increased BMAT often coinciding with decreased bone mass and
increased skeletal fragility (Scheller et al., 2016). BMAT can be
classified into two broad subtypes, regulated (rBMAT) and
constitutive (cBMAT), with the former typically showing greater
increases in conditions of bone fragility (Scheller et al., 2016).
There is also evidence to show that muscle disuse is associated with
an increase in BMAT (Gorgey et al., 2013). However, the impact of
DMD on BMAT has not been assessed previously.
The aim of this study was to further establish and compare the
bone structure and function, BMAT quantity, and growth
phenotypes of the mdx, mdx:Utrn+/− and mdx:Cmah−/− DMD
mouse models with the C57BL/10 wild-type (WT) mouse, and
determine which model would most closely mimic the clinical
characteristics of DMD.
We hypothesised that growth, growth plate (GP) chondrogenesis
and bone development are impaired in the muscular dystrophy
mouse models when compared toWTmice, andmore severely in the
mdx:Cmah−/− mouse model. In addition, rBMAT, but not cBMAT,
would be inversely associated with bone loss in each model.
Accurate characterisation of bone and growth would enable the
selection of an appropriate animal model when testing new therapies.
RESULTS
Grip strength and inflammation in muscular dystrophy
models
Histology of the tibialis anterior muscle revealed areas of necrosis
with a significant increase in the percentage of inflammatory cells
within all the muscular dystrophy models at 3 weeks of age
(Fig. 1A). There was evidence of muscle fibre necrosis and
regeneration with an increase in centrally located myonuclei and
fibre size variation by 5 and 7 weeks of age, which was particularly
noticeable in the mdx and mdx:Utrn+/− mice (Fig. 1Bii,iii). This is
compared to WT mice, whose muscle histology showed normal,
regular myofibres with peripheral nuclei and intact sarcoplasm at all
ages studied, with minimal evidence of inflammation or
regeneration (Fig. 1Ai,Bi,C). Grip strength (normalised to body
weight) was less in all muscular dystrophy models at 3 weeks of age
compared to WT mice (P<0.01; Fig. 1D). Reduced grip strength
was also noted in all muscular dystrophy models at 5 and 7 weeks of
age but the changes did not always reach significance (Fig. 1D).
Serum creatine kinase (CK) activity was >10-fold higher in all
muscular dystrophy mice and at all ages compared to WT mice,
providing further evidence for muscle damage in these muscular
dystrophy models (Fig. 1E).
Anthropometric measurements
Body weight and body length were measured from weaning
(3 weeks of age) (Table 1). No differences were observed in the
body weight of the mdx or mdx:Utrn+/− mice compared to WT at
any time point. In contrast, mdx:Cmah−/− mice were almost 2 g
lighter than WT mice at 3 weeks of age (8.07 g versus 10.03 g,
P=0.02), but were 3 g heavier by 7 weeks of age (21.97 g versus
24.97 g, P=0.02). Consistent with this, when analysing the mice that
were culled at 5 or 7 weeks of age (i.e. those with longitudinal
growth data available), the mdx:Cmah−/− mice gained significantly
more weight than WT mice from 3 to 5 weeks of age (8.77 g versus
10.61 g, P=0.01). Weight gain slowed between 5 and 7 weeks of
age in all models, and there were no genotype differences in weight
gain during this period (Fig. 1F). When genotype and age were
incorporated into a multivariable linear regression model, mdx:
Cmah−/− mice were associated with an increased growth rate
[coefficient (coeff ) 1.84, P<0.05] during the overall study period.
No differences in body weight were observed in the mdx or mdx:
Utrn+/− mice compared to WT mice at any time point studied.
Tibia length, growth rate and growth plate analysis
Tibia length from similarly aged WT and muscular dystrophy mice
was comparable, as was the rate of longitudinal bone growth
(assessed by calcein labelling); one exception was formdx:Cmah−/−
mice, which had an increased growth rate at 5 weeks of age (P=0.05;
Fig. 2). When genotype and age at cull were incorporated into a
multivariable linear regression model, mdx:Cmah−/− mice were
associated with an increased overall longitudinal bone growth rate
within the GP (coeff 18.6, P<0.01) compared withWT and the other
muscular dystrophy mouse models. Closer examination of the
proximal tibial GP of 3- and 7-week-old muscular dystrophy mice
also revealed no changes in total GP width or the width of the
proliferative and hypertrophic zones (Fig. S1). Similarly,
chondrocyte proliferation was unaffected in all of the muscular
dystrophy mice at 3 weeks of age (Fig. S1). We attempted to assess
the number of apoptotic hypertrophic chondrocytes in 7-week-old
mice, but the numbers of these cells were too sparse to enable
accurate quantification (data not shown).
Bone phenotype in the muscular dystrophy models
Very few structural changes were observed in the cortical bone of
the muscular dystrophy mice compared to WT mice (Table 2,
Table S1, Fig. 3A). Cortical bone area and cortical bone fraction
were lower in mdx:Cmah−/−mice compared to WT mice at 3 weeks
of age (P<0.05). However, in all 7-week-old muscular dystrophy
models, a higher cortical bone fraction was noted compared to WT
mice (P<0.05; Fig. 3B). Cortical tissue mineral density (TMD) was
higher inmdx:Cmah−/−mice at 3 (P<0.05) and 7 (P<0.01) weeks of
age and in mdx:Utrn+/− mice at 5 weeks (P<0.01) when compared
to WT mice (Fig. 3C). Trabecular tissue architecture was also
relatively unchanged in the various muscular dystrophy models
(Table 2, Table S2, Fig. 3A). The most stark difference was in
trabecular tissue volume, which was lower in mdx:Cmah−/−mice at
all ages studied, and this reached significance at 3 and 7 weeks of
age (P<0.001; Fig. 3D). Also, there was a trend for lower trabecular
connectivity in all muscular dystrophy mice, and this reached
significance in themdx:Utrn+/−mice at 5 weeks (P<0.05) and mdx:
Cmah−/− mice at both 5 and 7 weeks (P<0.01) when compared to
WT mice (Fig. 3E). The lack of a major bone phenotype was
reflected by the normal number of osteoblasts and osteoclasts
present on trabecular bone surfaces of the muscular dystrophy
models (Fig. 3F,G). Serum markers of bone formation and
resorption were also relatively normal in muscular dystrophy
mice, although αCTX concentrations were significantly higher in 3-
to 5-week-oldmdx:Cmah−/−mice (406.36±46.51 pg/ml) compared
to WT controls (181.70±78.51 pg/ml; P<0.01).
Biomechanical properties
Consistent with the small structural changes observed in the
trabecular and cortical compartments, there were limited differences
in the biomechanical properties of bones from WT and muscular
dystrophy mice. The only exception was a trend for lower deflection
at maximum load in mdx:Cmah−/−mice at all ages studied, and this
difference was significant in mice at 5 weeks of age (Table 3).
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Gene and protein expression studies
To identify more subtle changes in diaphyseal bone from muscular
dystrophy mice, we next used a PCR array to profile the expression
of 84 genes involved in skeletal development and/or bone mineral
metabolism. This analysis was limited to bone from 7-week-old
mice and revealed a 2- to 3.75-fold upregulation of matrix
Fig. 1. Muscle characteristics in different muscular dystrophy mouse models. (A) H&E-stained section of tibialis anterior from a 3-week-old: (i) WT mouse
showing normal, regular myofibres with peripheral nuclei and intact sarcoplasm; and (ii)mdx, (iii)mdx:Utrn+/− (shown asmdx:utr in the figure) and (iv)mdx:Cmah−/−
mouse, showing many inflammatory cells with a barely visible sarcoplasm. (B) H&E-stained section of tibialis anterior from a 7-week-old: (i) WT mouse
showing normal, regular myofibres with peripheral nuclei and intact sarcoplasm; and (ii)mdx, (iii)mdx:Utrn+/− and (iv)mdx:Cmah−/−mouse, showing regeneration
with larger myofibres and central nuclei. (C) Muscle cell inflammation was present in all muscular dystrophy models by 3 weeks of age followed by regeneration at
5 and 7 weeks of age. (D) Mean grip strength by age and genotype, showing a reduction in muscular dystrophy mice. (E) Higher CK activity in muscular dystrophy
mice at all ages. Data are presented as mean±s.d. (n>6); *P<0.05, **P<0.01, ***P<0.001 for cumulative measures of muscle damage compared to WT mice.
(F) Increased weight gain is seen in the young mdx:Cmah−/− mice. (Fi) Increased rate of weight gain in the mdx:Cmah−/− mice occurred between 3 and
5 weeks of age but not between 5 and 7 weeks of age. Data presented are mean (symbol) and standard deviation (whiskers). *P<0.05 compared to WT mice.
(Fii) Example of a growth chart for a WT mouse compared to an mdx:Cmah−/− mouse, showing the lower initial weight and the rapid growth velocity
seen in the early weeks in the mdx:Cmah−/− mouse.
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metalloprotease 10 (Mmp10) and bone morphogenetic protein
receptor type 1b (Bmpr1b) in all muscular dystrophy models
compared to WT mice (Table 4). In mdx:Cmah−/− mice, there was
also increased expression of growth and transcription factors
compared to WT control mice. In particular, there was increased
expression of insulin-like growth factor-1 (Igf1; 30-fold), IGF-1
receptor (Igf1R; 10-fold) and vascular endothelial growth factor A
(Vegfa; 32-fold) (Table 4).
Selected genes from this array were validated by
immunohistochemistry (IHC) to confirm the presence of IGF-1,
BMPR1b and MMP-10 proteins in tibial sections from WT and
muscular dystrophy mice. MMP-10 and BMPR1b were chosen
because they were upregulated in all muscular dystrophy mouse
models. IGF-1 was chosen because it is an essential factor in the
regulation of postnatal growth and showed a marked upregulation
in bone of mdx:Cmah−/− compared to WT mice. We were unable to
detect robust, positive staining for BMPR1b (data not shown). In
contrast, MMP-10 immunolocalisation was successful, but was
similar in all sections examined and no genotype-specific differences
in staining distribution or intensity were noted (data not shown). IHC
revealed greater IGF-1 staining of GP chondrocytes and cells
associated with trabecular bone within the metaphysis (Fig. 4A-C).
When quantified, IGF-1 staining intensity was significantly greater
in sections of mdx:Cmah−/− mice compared to WT mice (Fig. 4D).
BMAT quantification in tibiae
The proportion of total BMATwithin the tibial marrow cavity ofWT
and muscular dystrophy mice was similar. However, in comparison
to WT mice, the percentage of rBMAT (% rBMAT) was higher in
both mdx and mdx:Cmah−/− mice, whereas % cBMAT was lower
in both muscular dystrophy models (Fig. 5). Although the BMAT of
mdx:Utrn+/− mice was not studied, these observations suggest that
BMAT volume and distribution may be altered in DMD.
Metatarsal culture
To determine whether there was an intrinsic skeletal insult in these
muscular dystrophy models, we also investigated the growth
Table 1. Changes in growth parameters during the study period
Mouse type Time at analysis/comparisons
Body weight at cull (g)
3 weeks 5 weeks 7 weeks
WT 10.03 (1.62) 17.33 (0.98) 21.97 (1.42)
mdx 9.43 (1.23) 19.07 (2.13) 23.09 (2.90)
mdx:Utrn+/− 8.84 (0.55) 17.36 (1.59) 24.65 (1.62)
mdx:Cmah−/− 8.07 (0.90)* 17.17 (3.13) 24.97 (1.58)*
Gain in body weight (g)
From 3 to 5 weeks From 5 to 7 weeks
WT – 8.77 (2.24) 3.52 (1.34)
mdx – 7.93 (3.10) 4.05 (2.25)
mdx:Utrn+/− – 6.57 (3.53) 3.48 (1.30)
mdx:Cmah−/− – 10.61 (1.35)* 4.40 (0.95)
Crown-rump length (cm)
WT – 7.49 (0.84) 8.84 (0.39)
mdx – 8.09 (0.23) 8.93 (0.37)
mdx:Utrn+/− – 8.13 (0.38) 8.92 (0.22)
mdx:Cmah−/− – 8.01 (0.30)* 8.55 (0.36)
Tail length (cm)
WT – 6.86 (0.55) 7.56 (0.26)
mdx – 6.86 (0.20) 7.42 (0.18)
mdx:Utrn+/− – 6.98 (0.30) 7.74 (0.21)
mdx:Cmah−/− – 6.87 (0.33) 7.25 (0.51)
Data are presented as mean (±s.d.). *P<0.05 compared to WT mice of the
same age.
Fig. 2. Longitudinal bone growth rate in muscular dystrophy mouse models. (A) Longitudinal bone growth during the study period. Data are presented as
mean±s.d. *P<0.05 compared to WT mice of the same age. (B) Examples of calcein-labelled GP in a 5-week-old (i) mdx:Cmah−/− and (ii) mdx mouse, showing
the increased longitudinal growth rate in the mdx:Cmah−/− mouse (red arrows).
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potential of bones from WT, mdx and mdx:Cmah−/− mice in an
ex vivo organ culture model. Over a 7-day period, the growth of
metatarsals from muscular dystrophy and WT mice was similar
(Fig. S1D).
DISCUSSION
We have demonstrated a significant muscle phenotype in all three
muscular dystrophymodels, and also confirmed age- and strain-related
characteristics. Consistentwith published data, themdx:Cmah−/−mice
exhibited a marked muscle phenotype (Chandrasekharan et al., 2010).
This is consistent with the theory that lower levels and function of the
dystrophin-glycoprotein complex and metabolic accumulation of
dietary N-glycolylneuraminic acid, which occur as a consequence
of the Cmah mutation, contribute to a more-severe muscle
phenotype. Indeed, our analyses of muscle histology and serum
CK further demonstrate that mdx mice have a greater capacity for
muscle regeneration than themdx:Utrn+/− ormdx:Cmah−/−models. In
keeping with this, normalised grip strength was significantly lower in
mdx compared toWTat 3 weeks of age, but not beyond this time point.
This is consistent with published data on the mdx mouse suggesting
that there is an early period, between the end of the second and up to
the fifth week of life, when the mice experience histological necrosis
and functional weakness. After this critical period, regeneration occurs
and there are no co-existing clinical features ofDMD, such as scoliosis
and heart failure, until mice are at least 15 months or older (Bulfield
et al., 1984; Muntoni et al., 1993; Lefaucheur and Sebille, 1995;
Chamberlain et al., 2007; Coley et al., 2016). Like all the muscular
dystrophy models that we tested, serum CK activity is significantly
higher inmdx:Utrn+/−mice than WT mice, and muscle histology also
demonstrated ongoing inflammation and regeneration at 5 and 7 weeks
of age. However, the normalised grip strengthwas lower thanWTmice
only at 3 weeks of age. Other studies have also reported a variable
muscle phenotype (Huang et al., 2011; Mcdonald et al., 2015).
Our study is the first to describe the growth and bone phenotypes
of the mdx:Cmah−/− and mdx:Utrn+/− mouse. It was expected that
there would be a growth phenotype in all the muscular dystrophy
models and that it would be most severe in the mdx:Cmah−/− mice.
However, our results do not support this and, despite the marked
muscle phenotype, we find no evidence of a more severe skeletal
phenotype in mice of up to 7 weeks of age. Unexpectedly, despite
being bred in exactly the same conditions and during the same
season, the mdx:Cmah−/− mice are smaller than the WT mice at
3 weeks of age, but demonstrated increasedweight gain such that, by
7 weeks of age, they are heavier thanWTmice. The smaller absolute
body weight in the youngestmdx:Cmah−/−mice may be a reflection
of several factors, including poorer general health in the mothers
prior to or during pregnancy, or a problem pre- or peri-weaning in the
offspring. Consistent with this, the mdx:Cmah−/− mice were much
harder to breed than expected and there were a higher than expected
number of pre-wean deaths. The catch-up growth is suggested by
gross body weight measures but also at the GP level through
dynamic histomorphometry using calcein labelling. Additional
evidence for the catch-up growth is found in the upregulation of
many growth factors on the PCR array, including a 30-fold increase
in Igf1 expression and 60-fold increase in Vegfa expression. Further
evidence of increased bone turnover in the young mdx:Cmah−/−
mice compared to WT mice is suggested by the higher levels of
α-CTX, a marker of bone resorption. Although levels of the bone
formationmarker, P1NP, were not raised at this age, it is possible that
it may have risen subsequently.
We did not find any evidence of growth retardation in either themdx
or mdx:Utrn+/− mice compared to WT mice at any age. Consistent
with our data showing no difference in tibial length (Table S3),
Nakagaki showed no significant difference in femur length between
mdx and WT mice at 3 week of age (Nakagaki et al., 2011).
There are conflicting data regarding the bone phenotype in the
mdx mouse and, unlike in patients with DMD, where bone strength
decreases with advancing age, the converse appears true in some
studies of mdx mice (Anderson et al., 1993). Osteopenia has also
been demonstrated in young mdx mice (Anderson et al., 1993;
Nakagaki et al., 2011; Novotny et al., 2011). By contrast, other
studies have shown either no difference in any µCT parameters
between young mdx and WT males, or a paradoxical increase in
femoral bone mineral density on dual-energy X-ray absorptiometry
in older female mdx mice compared to WT mice (Montgomery
et al., 2005; Isaac et al., 2013). We have shown a higher cortical
bone fraction in mdx mice compared to WT mice, but only at
7 weeks of age, and no difference was observed in any other
parameters on micro-computed tomography (µCT), bone turnover
markers or on biomechanical testing. This may reflect the muscle-
bone crosstalk and the potential for an adaptive bone response
alongside the muscle regeneration in the mdx model.
Compared to the mdxmouse, data reporting on the bone structure
of mdx:Utrn+/− mice is restricted to collagen content of the
metaphyseal bone, which is less in mdx:Utrn+/− mice compared to
mdx andWTmice (Isaac et al., 2013). This present study also shows
no conclusive evidence of altered bone structure in mdx:Utrn+/−
mice. Our µCT data show, paradoxically, that TMD is higher in the
mdx:Utrn+/− mice compared to WT mice at 5 weeks of age only,
while cortical bone fraction is also greater thanWTmice, but only in
those culled at 7 weeks.
Table 2. Key trabecular and cortical parameters of tibiae from WT and
muscular dystrophy mouse models as assessed by µCT
Mouse type 3 weeks at cull 5 weeks at cull 7 weeks at cull
Cortical tissue volume (mm3)
WT 0.45 (0.20) 0.59 (0.14) 0.71 (0.23)
mdx 0.34 (0.16) 0.72 (0.06) 0.68 (0.20)
mdx:Utrn+/− 0.45 (0.14) 0.73 (0.05) 0.51 (0.20)
mdx:Cmah−/− 0.48 (0.06) 0.69 (0.06) 0.86 (0.08)
Cortical bone volume (mm3)
WT 0.22 (0.11) 0.34 (0.09) 0.44 (0.15)
mdx 0.15 (0.07) 0.43 (0.04) 0.44 (0.12)
mdx:Utrn+/− 0.20 (0.06) 0.44 (0.02) 0.33 (0.13)
mdx:Cmah−/− 0.20 (0.03) 0.41 (0.04) 0.56 (0.07)
Cortical bone fraction (%)
WT 46.62 (4.55) 56.63 (5.57) 61.98 (1.66)
mdx 44.56 (3.30) 59.31 (1.51) 65.30 (2.20)*
mdx:Utrn+/− 45.76 (1.02) 59.56 (2.50) 65.50 (2.09)*
mdx:Cmah−/− 41.46 (4.50)* 60.10 (1.61) 64.64 (2.64)*
Trabecular tissue volume (mm3)
WT 1.48 (0.27) 1.91 (0.36) 2.38 (0.16)
mdx 1.24 (0.09) 1.90 (0.15) 2.15 (0.35)
mdx:Utrn+/− 1.17 (0.09) 1.79 (0.27) 2.37 (0.22)
mdx:Cmah−/− 1.03 (0.22)*** 1.54 (0.19) 1.84 (0.14)***
Trabecular bone volume (mm3)
WT 0.11 (0.03) 0.19 (0.05) 0.32 (0.07)
mdx 0.08 (0.02) 0.16 (0.04) 0.24 (0.08)
mdx:Utrn+/− 0.08 (0.01) 0.14 (0.04) 0.25 (0.07)
mdx:Cmah−/− 0.08 (0.02) 0.16 (0.03) 0.25 (0.05)
Trabecular bone/tissue volume (%)
WT 6.78 (0.79) 9.71 (1.61) 13.28 (2.34)
mdx 6.55 (1.17) 8.36 (1.55) 11.16 (2.23)
mdx:Utrn+/− 6.82 (1.10) 7.83 (1.32) 10.49 (1.90)
mdx:Cmah−/− 8.30 (1.15) 10.36 (1.88) 13.54 (2.24)
Data are presented as mean (±s.d.). n>6; *P<0.05, ***P<0.001 compared to
WT mice.
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Fig. 3. Boneparameters inmuscular dystrophymousemodels. (A) Representative µCT images of tibial bone of all genotypes at 3, 5 and 7 weeks of age to show
bone development (upper row, mid diaphyseal cortical bone; lower row, metaphyseal trabecular bone). (B) Compared to similarly aged WT mice, cortical bone
fraction was lower in mdx:Cmah−/− mice at 3 weeks of age, but higher in all muscular dystrophy models at 7 weeks of age. (C) Cortical tissue mineral density was
higher in mdx:Cmah−/− mice at 3 and 7 weeks of age and in mdx:Utrn+/− (shown as mdx:utr in the figure) mice at 5 weeks when compared to WT mice.
(D) Trabecular tissue volumewas lower inmdx:Cmah−/−mice at 3 and 7 weeks of age compared withWT. (E) Trabecular connectivity was lower inmdx:Utrn+/−mice
at 5 weeks andmdx:Cmah−/−mice at both 5 and 7 weeks when compared toWTmice. (F,G) The number of osteoblasts (F; N.Ob/BS) and osteoclasts (G; N.Oc/BS)
per bone surface were normal in all muscular dystrophy models at 5 weeks of age. Data are presented are mean±s.d. (n>6); *P<0.05, **P<0.01, ***P<0.001
compared to WT mice.
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Although we hypothesised that mdx:Cmah−/− mice would have
osteoporosis, their TMD is increased compared to WT mice at both
3 and 7 weeks of age, and cortical bone fraction is also higher at
7 weeks of age. This may be due to a compensatory bone response
to muscle damage and then regeneration as described for mdxmice,
but there may also be other factors responsible. For example, one
study demonstrated that the CMAH gene is upregulated in adult
human stem cells, of both haematopoietic and mesenchymal origin.
Overexpression of the human CMAH gene causes accumulation of
nuclear β-catenin (Nystedt et al., 2009) and associated restriction of
Wnt signalling. Therefore, it is possible that the absence of the
Cmah gene in the mdx:Cmah−/− mouse model may cause a
reduction in nuclear β-catenin expression and unregulated Wnt
signalling, and thereby promote the osteoblast lineage and bone
formation (Westendorf et al., 2004).
We found that all the muscular dystrophy models have an
upregulation of Mmp10 and Bmpr1b gene expression compared to
WT mice. Matrix metalloproteases (MMPs) are members of a
family of calcium-dependent proteinases that can cleave a wide
range of extracellular proteins, including components of the
extracellular matrix. MMP-10 is known to be involved in bone
growth but has also been shown to be involved in tissue repair
processes and specifically in muscular dystrophy mouse models
(Ortega et al., 2004). Increased skeletal muscle MMP-10 protein
expression has been demonstrated in response to the damaged,
dystrophic muscle seen in themdxmouse (Ortega et al., 2004). This
may also explain our finding that Mmp10 is upregulated in bone,
because the bone-muscle unit is intrinsically interlinked (Veilleux
and Rauch, 2017). Growth factors of the transforming growth factor
(TGFβ) family, which includes bone morphogenetic proteins
(BMPs), play an important role in skeletal development (Chen
et al., 2012), and BMP signalling in particular has been shown to
lead to the expression and activity of genes necessary for osteoblast
differentiation (Song et al., 2009). Increased BMP signalling has
also been implicated in the pathogenesis of DMD, and recent studies
have suggested an essential role of BMPs and also the type 1
receptor in regeneration after muscle damage (Shi et al., 2013).
Thus, our findings of increased skeletal Bmpr1b expression in mdx,
mdx:Utrn+/− andmdx:Cmah−/−mice are consistent with their use as
preclinical muscular dystrophy models.
Our finding of catch-up growth inmdx:Cmah−/−mice has further
implications for understanding the putative role of Cmah in other
diseases. Thus, Cmah-null mice have been proposed as one of the
best to mimic the phenotype of human metabolic disorders (Kavaler
et al., 2011; Kwon et al., 2015). We speculate that this metabolic
dysregulation may relate to altered developmental programming in
Cmah-null mice. According to the Barker hypothesis and the
developmental origins of health and disease, predisposition to the
development of the metabolic syndrome begins in utero during
critical periods of foetal development. During such periods,
changes occur to promote foetal survival in the adverse
intrauterine environment, but, in later life, these changes can also
have a lasting impact on health and the development of the
metabolic syndrome. The mdx:Cmah−/− mice in this study were
smaller than expected for the C57BL/10 background and displayed
catch-up growth, in keeping with the ‘thrifty phenotype’, but the
process and the exact role of the Cmah mutation remains unclear.
One possibility is that these mice have mitochondrial dysfunction
caused by oxidative stress, but it is unclear whether this is a cause or
consequence of their insulin resistance (Kwon et al., 2015).
The assessment of BMAT provided some very interesting and
unexpected findings. We have shown that there is a significant
increase in rBMAT in both the mdx and mdx:Cmah−/− mice, but a
Table 3. Biomechanical properties of tibiae from WT and muscular
dystrophy mouse models as assessed by 3-point bending
Mouse type 3 weeks at cull 5 weeks at cull 7 weeks at cull
Maximum load (N)
WT 3.16 (1.68) 7.42 (3.11) 6.87 (4.57)
mdx 5.33 (8.12) 5.16 (0.80) 9.30 (2.94)
mdx:Utrn+/− 3.69 (3.76) 4.49 (0.55) 10.62 (3.01)
mdx:Cmah−/− 1.77 (0.37) 4.47 (1.17) 7.10 (0.92)
Deflection at max load (mm)
WT 1.21 (0.15) 1.58 (0.66) 1.07 (0.58)
mdx 1.92 (1.36) 1.07 (0.51) 1.31 (0.58)
mdx:Utrn+/− 1.14 (0.37) 1.19 (0.06) 1.61 (0.70)
mdx:Cmah−/− 0.69 (0.31) 0.72 (0.26)* 0.74 (0.28)
Stiffness (N/mm)
WT 19.24 (16.6) 33.41 (28.41) 37.27 (3.44)
mdx 11.27 (12.6) 17.11 (5.21) 25.69 (14.18)
mdx:Utrn+/− 14.84 (14.3) 11.39 (3.21) 25.59 (15.25)
mdx:Cmah−/− 9.09 (5.92) 17.20 (6.87) 19.46 (4.65)
Data are presented as mean (±s.d.). *P<0.05 compared to WT mice.
Table 4. Transcripts on qPCR array that were overexpressed in
muscular dystrophy models compared to WT
Transcript
Fold
regulation P-value
mdx versus WT
Bone morphogenetic protein receptor,
type 1 B (Bmpr1b)
2.69 0.04
Matrix metallopeptidase 10 (Mmp10) 2.03 0.00001
mdx:Utrn+/− versus WT
Bone morphogenetic protein 6 (Bmp6) 3.6 0.008
Bone morphogenetic protein receptor,
type 1 B (Bmpr1b)
2.29 0.00001
Fibroblast growth factor 2 (Fgf2) 3.16 0.04
Integrin alpha M (Itgam) 11.04 0.04
Matrix metallopeptidase 10 (Mmp10) 2.39 <0.00001
Noggin (Nog) 3.56 0.006
Tumour necrosis factor (Tnf) 2.38 0.0009
mdx:Cmah−/− versus WT
Alpha-2-HS-glycoprotein (Ahsg) 3.51 0.04
Bone morphogenetic protein 2 (Bmp2) 3.24 0.02
Bone morphogenetic protein receptor,
type 1 B (Bmpr1b)
3.63 0.000001
Colony stimulating factor 3, granulocyte
(Csf3)
4.05 <0.00001
Epidermal growth factor (Egf) 4.68 0.05
Intercellular adhesion molecule 1 (Icam1) 6.18 0.01
Insulin-like growth factor 1 (Igf1) 30.58a 0.01
Insulin-like growth factor 1 receptor (Igf1r) 9.98 0.05
Indian hedgehog (Ihh) 4.08 <0.00001
Integrin alpha 2b (Itga2b) 4.19 0.02
Integrin alpha 3 (Itga3) 4.85 0.003
Matrix metallopeptidase 10 (Mmp10) 3.75 <0.00001
Matrix metallopeptidase 8 (Mmp8) 7.64 0.005
Noggin (Nog) 5.69 0.0008
SRY-box containing gene 9 (Sox9) 6.18 0.02
Tumour necrosis factor (Tnf) 4.11 0.01
Vascular cell adhesion molecule 1 (Vcam1) 4.03 0.02
Vascular endothelial growth factor A (Vegfa) 32.39a 0.002
Vascular endothelial growth factor B (Vegfb) 7.82 0.04
Transcripts are included whereP-value for change in fold regulationwas <0.05.
aTranscripts with an average threshold cycle that was relatively high (>30) in
the control or the test sample but relatively low (<30) in the other sample. These
data indicate that the transcript’s expression is relatively low in one sample but
readily detected in the other sample, suggesting that the actual fold-change
value is at least as large as the calculated and reported fold-change result.
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marked decrease in cBMAT. The causes and consequences of this
increase, as well as its clinical relevance, warrant further
investigation. Several mechanisms might account for the altered
BMAT. Studies have shown that rBMAT is increased during obesity
and, paradoxically, also during caloric restriction (Devlin, 2011;
Cawthorn et al., 2014), whereas loss of cBMAT is less common
and is most pronounced in lipodystrophic conditions. This indicates
modulation of BMAT in states of altered systemic energy
homeostasis. The role of dystrophin in the regulation of
metabolism is poorly understood and is difficult to evaluate
clinically as body composition in DMD is confounded by the long-
term use of high-dose GCs. However, a recent study demonstrated
that dystrophin deficiency in themdxmouse resulted in reduced body
fat (confirmed by DEXA body composition studies) and a
consistently lower core body temperature, despite no overall body
weight difference between the mdx and WT mice (Strakova et al.,
2018). Similar studies have shown increases in energy expenditure
and muscle protein synthesis in the mdx mouse, and an altered
response to high-fat diet compared to C57BL/10 controls (Radley-
Crabb et al., 2011, 2014). The differences were found in spite of a
higher level of food consumption. Thus, it is possible that the increase
in rBMAT occurs as a response to altered energy homeostasis in the
DMD mice. In humans, increased BMAT is associated with
increased plasma lipids (Scheller et al., 2016); however, studies
examining serum lipid levels have shown no difference betweenmdx
and WT mice (Milad et al., 2017). In contrast, mdx mice appear to
have defects in expansion of primary adipose progenitor cells in vitro
(Joseph et al., 2018), and therefore altered BMAT may also relate to
differences in adipose progenitor cells.
The consequences of altered BMAT are also interesting to
consider. Marrow adipocytes have been suggested to regulate
skeletal remodelling, haematopoiesis and metabolic homeostasis.
Moreover, logic dictates that accumulation of rBMAT in proximal
tibia must occur at the expense of either haematopoiesis or bone,
given the finite size of the marrow cavity. Consistent with this, we
found that trabecular bone is decreased in 7-week-oldmdx:Cmah−/−
mice. However, cortical bone in each muscular dystrophy model
was increased at 7 weeks of age, which is at odds with the increased
rBMAT. It would be worth assessing haematopoiesis in these mice,
given the potential for BMAT to modulate this process. Clinically,
osteoporosis has been associated with a decrease in BMAT
unsaturation (Yeung et al., 2005) and bone-marrow fat
composition has been suggested as a useful biomarker in post-
menopausal women with fragility fractures (Patsch et al., 2013).
Thus, altered BMAT may also have a useful prognostic role in
DMD. Future studies should explore these possibilities.
Conclusion
In conclusion, our results confirm that all three of the DMD mouse
models examined showed marked muscle damage and impaired grip
strength as expected and consistent with the literature. We have also
demonstrated differences inBMATcomposition,whichmayserve as a
potential biomarker for bone fragility in patients with DMD.However,
we find no consistent bone or growth defect in anyof theDMDmodels
at all ages studied. This may become apparent in older mice, but it is
likely that, to mimic more closely the osteoporosis and growth
retardation that are observed in boys with DMD, glucocorticoids must
be given to the mice. In particular, we find that the mdx:Cmah−/−
mouse certainly does not mimic the growth trajectory of boys with
DMD, but instead appears to display catch-up growth and increased
bone turnover with a resultant increase in TMD and cortical bone
fraction. Rather than being a useful murine model for growth
retardation andosteoporosis inDMD, themdx:Cmah−/−mousemay in
fact be useful when a model of catch-up growth is desired.
MATERIALS AND METHODS
Animals and experimental procedures
Four different mouse strains were examined: wild-type (WT; C57BL/
10ScSnJ); mdx (C57BL/10ScSn.mdx); mdx:Utrn (C57BL/10ScSn.utrn/
mdx); and mdx:Cmah−/− (B10.Cg-CMahtm1AvrkDmdmdx/PtmJ). All mice
were obtained from Jackson Laboratories (New Harbour, MA, USA). All
animal experiments were approved by the Roslin Institute’s Animal Users
Committee, and mice were maintained in accordance with Home Office
(UK) guidelines for the care and use of laboratory animals. All mice were
housed under controlled temperature (approx. 25°C) and light conditions
(12 h light:12 h dark cycle), and had access to food and water ad libitum.
A cross-sectional study was performed whereby mice were culled at three
developmental ages (3, 5 and 7 weeks of age). Aminimum of 6male mice of
each genotype were used at each time point. Additional mice were used
for the assessment of marrow adiposity. Body weight, crown-to-rump and
tail-length measurements were taken twice weekly using digital weighing
scales and a ruler.
Grip strength
Forelimb grip strength testing was performed within 24 h prior to culling,
using a grip strength meter with a specialised mouse grid (Harvard
Biosciences, MA, USA), according to the TREAT-NMD standard operating
protocol (Luca, 2014). The mean of three consecutive measurements was
calculated and normalised to body mass.
Muscle histology
The tibialis anterior muscles were removed and fixed in 4%
paraformaldehyde (PFA) before undergoing paraffin wax embedding.
Fig. 4. IGF-1 immunohistochemistry in muscular dystrophy mouse
models. Immunolocalisation of IGF-1 in sections of (A) WT and (B) mdx:
Cmah−/− tibiae, showing greater staining intensity in cells of both ossification
centres and the growth plate (GP). (C) Control section in which rabbit IgG was
substituted for the primary antibody. (D) Quantification of IGF-1 staining in GP
chondrocytes and metaphysis of tibiae from WT and muscular dystrophy
mouse models. Data are presented as mean±s.d. (n=6). *P<0.05, **P<0.01
compared to WT mice.
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Sections (6 µm) were stained with Haematoxylin and Eosin (H&E) for
histological assessment, according to the TREAT-NMD protocol (Grounds,
2014). Images were acquired using a Zeiss AxioImager brightfield
microscope and analysed using Fiji (Schindelin et al., 2012). The
percentage of inflammatory cells in the region of interest (ROI) was
calculated and the number of central nuclei (signifying muscle regeneration)
recorded, to obtain a cumulative measure of skeletal muscle damage.
Serum measurements
Immediately following euthanasia, blood was obtained from non-fasted
animals via cardiac puncture. Serum CK concentration was measured by a
CK assay kit (Pointe Scientific, Stroud, UK) in samples collected at 3, 5 and
7 weeks of age. Serum P1NP and αCTX was measured by ELISA (AMS
Biotechnology, Abingdon, UK) at 3 weeks of age.
Micro-CT analysis
Micro-computed tomography imaging (µCT) was performed to quantify
trabecular architecture, cortical bone geometry, TMD and tibia length. Left
tibiae were dissected from all mice, stored in H2O at −20°C and thawed prior
to scanning with a SkyScan 1272 X-ray microtomograph (Bruker
Corporation, Kontich, Belgium). The bones were wrapped in paper tissue
and enclosed at a consistent vertical height in tightly fitting rigid plastic tubes
filled with water, to prevent movement artefacts. Two images were averaged
at each rotation angle to reduce noise. For trabecular bone, images were
obtained at a 4.5 µm resolution, using a 0.5 mm aluminium filter and 0.3°
rotation step. For cortical bone image accrual and tibial lengthmeasurements,
images were obtained at a 9 µm resolution using a 0.5 mm aluminium filter
with a 0.5° rotation step. Scans were reconstructed using NRecon software
(Bruker) and a volume of interest was selected using Data Viewer software
(Bruker). Two hundred slices of the metaphysis were taken for analysis of
trabecular bone, with the ROI starting 10 slices below the base of the growth
plate (GP). One hundred slices of the diaphysis were taken for analysis of
cortical bone, with the ROI starting 50 slices above the tibia-fibula junction.
CTAn software (Bruker) was used to analyse appropriate parameters. Cortical
TMD was calculated using hydroxyapatite rod pair phantoms of a known
density (0.25 g/cm3 and 0.75 g/cm3), which were scanned using the same
settings used for cortical image accrual. Tibial length was measured from the
proximal tibial plateau to the distal tip of the medial malleolus.
Bone marrow adiposity
Marrow adiposity was assessed by osmium tetroxide staining of intact right
tibiae of 7-week-old mice, as previously described (Scheller et al., 2014).
Fig. 5. Bone marrow adiposity in muscular dystrophy mouse models. Three-dimensional µCT reconstructions of 7-week-old osmium-stained tibiae from:
(A) WT, (B) mdx and (C) mdx:Cmah−/− mice. Bone appears grey and BMAT is white. (D) The boundaries of rBMAT and cBMAT within the tibia are shown;
rBMAT lies proximal to tibia/fibula junction and cBMAT lies distal to tibia/fibula junction (shown by dashed line). (E-G) Percentage of (E) total BMAT, (F) rBMAT,
(G) cBMAT. Data are presented as mean±s.d. (n=5). *P<0.05, **P<0.01 compared to WT mice. Ad.V/Ma.V, adipose volume/marrow volume.
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Tibiae were fixed in neutral-buffered formalin for 1 week, scanned by µCT
imaging, decalcified in 14% ethylenediaminetetraacetic acid (EDTA) for
2 weeks at 4°C and then stained with 1% osmium tetroxide solution for 48 h
before further µCT imaging. The volumes of total, regulated (r) and
constitutive (c) BMAT (Ad.V) were determined and calculated as the
percentage of the marrow cavity volume (Ma.V), which was determined by
µCT prior to staining (Scheller et al., 2015).
Biomechanical testing
Three-point bending analysis of the cortical region of the left tibiae was
carried out immediately after µCT, using a Lloyd LRX5 materials testing
machine (Lloyd Instruments, West Sussex, UK). A 100 N loading cell was
used with the span fixed at 10 mm and the cross-head lowered at 1 mm/min
to determine load to failure and maximum stiffness and deflection of tibiae
(Huesa et al., 2011).
Bone histomorphometry
Two days prior to sacrifice, the mice received an intraperitoneal injection of
30 mg/kg body weight calcein. After dissection, the right femur was fixed in
4% PFA for 24 h, transferred to 70% ethanol and then embedded in methyl
methacrylate to allow quantification of longitudinal growth rate at the
chondro-osseous junction (Owen et al., 2009; Dobie et al., 2015). Right
tibiae were de-calcified for 3 weeks in 10% EDTA and processed to wax
using standard procedures. Sections were stained with Toluidine Blue to
enable calculation of total and zonal widths of proliferating and hypertrophic
zones of the GP (Owen et al., 2009). Static histomorphometry was
performed on paraffin-embedded, decalcified sections of tibiae from mice
culled at 5 weeks of age. Tartrate-resistant acid phosphatase (TRAP) activity
and Fast Red staining was used to identify osteoclasts (TRAP+ve) as
multinucleated cells lying on the bone surface. Osteoblasts were visualised
by their cuboidal appearance and by the presence of alkaline phosphatase
(ALP) activity. Images from 5-week-old mice were scanned using a
Nanozoomer slide scanner (Hamamatsu Photonics, Japan) and then the
trabecular area of the proximal tibia were analysed. The ROI included only
metaphyseal trabecular bone and extended from 50 µm below the GP
and within the endocortical bone boundary. Osteoblast and osteoclast
numbers per bone surface were determined using BioqantOsteo v 11.2.6
(Bioquant Image Analysis Corp, Nashville, TN, USA), in accordance with
the American Society of Bone and Mineral Research Guidelines for
nomenclature (Dempster et al., 2013).
Assessment of chondrocyte proliferation and apoptosis
The ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (EMD
Millipore, Bedford, MA, USA) was used as per manufacturer’s instructions
to quantify the number of apoptotic cells in the tibial GP of 7-week-old
mice. Proliferating cell nuclear antigen (PCNA) immunohistochemistry
(IHC) was performed using a 1:4000 dilution of an anti-PCNA antibody
(Abcam, Cambridge, UK) followed by the Vectastain elite ABC rabbit
kit (Vector Laboratories, Peterborough, UK) on paraffin-embedded sections
from 3-week-old mice (when rates of proliferation were likely to be highest).
Sections were counterstained by Haematoxylin and viewed using a
Zeiss AxioImager brightfield microscope. The Haematoxylin-DAB
colour deconvolution plugin was used in Fiji to calculate the
percentage of PCNA+ve cells in the proliferating zone of the GP of
each sample.
RNA extraction and PCR array
The epiphyses of the right humerus of 7-week-old mice were removed and
the shaft centrifuged to remove the bone marrow. Thereafter, cortical bone
shaft was snap frozen in liquid nitrogen. RNA was extracted using a
modified version of the Qiagen RNeasy kit (Manchester, UK) and reverse
transcribed using standard procedures. The cDNAwas analysed on the real-
time RT2 profiler PCR osteogenesis pathway 84-gene array (Qiagen,
Manchester UK), in combination with RT2 SYBR Green qPCR Mastermix
(Qiagen, Manchester, UK) in a Stratagene Mx3000P PCR cycler
(Stratagene, CA, USA). Relative gene expression for each gene was
calculated in the muscular dystrophy mouse models compared to the WT
control group using the 2-ΔΔCT method (Livak and Schmittgen, 2001).
ΔCT for each sample was normalised using the geometric mean of the
Gapdh housekeeping reference gene (included within the array) as this was
found to be the most consistent of the 5 housekeeping genes included in the
RT2 osteogenesis array (Gusb, Actb, B2m and Hsp90ab1 also tested) across
all samples analysed. CT values of >35 cycles were considered non-specific
and discarded.
Immunohistochemistry
A standard indirect IHC procedure was used to detect IGF-1, BMPR1b and
MMP-10 expression (Dobie et al., 2015). Primary antibodies were anti-IGF-
1 (Abcam, ab9572, 1:500 dilution), BMPR1b (Abcam, ab175385, 1:100
dilution) and MMP-10 (Abcam, ab199688, 1:100 dilution). Control
sections were incubated with an equal amount of rabbit IgG in place of
the primary antibody. Sections were counterstained by Haematoxylin,
mounted and images captured using a Zeiss AxioImager brightfield
microscope. Fixation and antigen retrieval were carried out using the
samemethodology throughout and all IHC for each antibody was performed
on the same day under identical conditions, with control specimens also
tested for each genotype. After the images were imported into Fiji, the
Haematoxylin-DAB colour deconvolution plugin was used to separate the
Haematoxylin and DAB components, and the ‘analyse-measure’ tool used
to determine the absorbance in a consistent region of each sample,
containing both GP and metaphyseal bone. Optical density (OD) was then
calculated using the equation: OD=negative (base10)log of mean intensity
of transmitted image/illumination (max intensity of image).
Maximum intensity was taken to be 255 for 8-bit images in Fiji (Ruifrok
and Johnston, 2001).
Metatarsal culture
Embryonic (day 18) metatarsal culture was performed as previously
described (Houston et al., 2016). The middle three metatarsals were cultured
for 10 days and the total length of the metatarsal was measured at day 0, 3, 5
and 7 days using a Nikon Eclipse TE300 microscope with a digital camera
attached and Image Tool software (Image Tool Version 3.00, San Antonio,
TX, USA).
Statistical analysis
Mice were identified only by number at the time of culling, to enable
blinding by genotype. For clarity, the mdx:Cmah−/− mice are referred to as
mdx:Cmah, and mdx:Utrn+/− mice as mdx:Utrn. Statistical comparisons
were made between mice of each genotype and age, using STATA v15 and
GraphPad Prism v7. After checking for normality of data, 1-way ANOVA
was used to assess significance of differences between groups and post-test
Bonferroni modifications were made to adjust for multiple comparisons.
Data are presented as mean±s.d. A P-value of <0.05 was accepted as
significant. Linear multivariable regression models were used when
appropriate to estimate the relationship between the outcome variable
under investigation and other independent variables, after adjustment for
any potential confounders. Following model generation, regression
diagnostics were performed to check the underlying assumptions of the
linear model. Residual normality was checked using a normal probability
plot and a residual versus fitted plot drawn to ensure that the variance of
errors was constant throughout the range of residuals. µCT data were also
standardised for tibial length and body weight at cull, but significant results
remained the same and therefore only unadjusted data are shown.
Quantitative real-time PCR (qPCR) raw data were analysed using the
Qiagen web-based PCR array data analysis tool. In accordance with this, P-
values were calculated based on a Student’s t-test of the CT data, and a fold
change >1 was considered as upregulation and <−1 as downregulation.
This article is part of a special collection ‘A Guide to Using Neuromuscular Disease
Models for Basic and Preclinical Studies’, which was launched in a dedicated
issue guest edited by Annemieke Aartsma-Rus, Maaike van Putten and James
Dowling. See related articles in this collection at http://dmm.biologists.org/collection/
neuromuscular.
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